https://www.selleckchem.com/pr....oducts/tinengotinib.
Intended technical success rates of primary and secondary endoscopic reintervention were 93.6% (44/47) and 87.5% (7/8), respectively (p=0.47). Clinical success rates were 72.3% and 50%, respectively (p=0.23). Stent malfunction rate after reintervention was 48.9% (23/47) and 37.5% (3/8) (p=0.7 during follow up, and median cumulative stent patency duration was 119 days and 55 days, respectively (Log-rank p=0.68). Stent patent rate after reintervention was not different according to the time interval. In univariate and multivariate
Like
Comment
Share
